chrisvoncsefalvay/vaers-outcomes huggingface dataset:
The day after my shot  I woke up with extreme joint pain; mostly throughout my leg, ankles and toes, as well as my hips. Stairs were extremely painful. By Sunday 4/4 the pain had subsided. Around 4/6, I noticed raised red bumps all over my elbows which turned to white patches forming over them within a day or so. After seeing the dermatologist 4/13, she informed me it was psoriasis which could also lead to psoriatic arthritis. (Seems like what I felt 4/3). She prescribed Mometasone cream to be used 2x a day for the rash. The bumps still remain today 4/23 but have diminished slightly and lost the white patch on them. This past week starting around 4/19, my arm and shoulder (of the arm I received the shot in) has had a dull ache 24/7, seemingly muscular.
swelling/big oval circle; puffy; warm to touch; injection site became red/its still red spot at injection site/two and quarter in inches/reduce to inch and half; This spontaneous case was reported by a consumer and describes the occurrence of SWELLING (swelling/big oval circle), SKIN SWELLING (puffy), FEELING HOT (warm to touch) and INJECTION SITE ERYTHEMA (injection site became red/its still red spot at injection site/two and quarter in inches/reduce to inch and half) in a 78-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 024M20A) for COVID-19 vaccination.     Concomitant products included LEVOCETIRIZINE DIHYDROCHLORIDE (XYZAL) and VITAMINS NOS for an unknown indication.    On 10-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 25-Mar-2021, the patient experienced INJECTION SITE ERYTHEMA (injection site became red/its still red spot at injection site/two and quarter in inches/reduce to inch and half). On an unknown date, the patient experienced SWELLING (swelling/big oval circle), SKIN SWELLING (puffy) and FEELING HOT (warm to touch). At the time of the report, SWELLING (swelling/big oval circle), SKIN SWELLING (puffy) and FEELING HOT (warm to touch) outcome was unknown and INJECTION SITE ERYTHEMA (injection site became red/its still red spot at injection site/two and quarter in inches/reduce to inch and half) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant information were not provided. Treatment information were not provided.
Fever - 102.4 F; Moderate fatigue; Severe headache; Moderate chills; Moderate muscle pain; Moderate joint pain; This is a spontaneous report from a contactable consumer, the patient. A 58-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EZ8729), via an unspecified route of administration in the left arm on 09Apr2021 at 09:15 (at the age of 58-year-old), as a single dose for COVID-19 immunisation. Medical history was reported as none and the patient did not have a history of allergies to any food or medications or other products. The patient did not receive any other medications within two weeks of vaccination. The patient previously received first dose of  BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6201), via an unspecified route of administration in the left arm on 12Mar2021 at 10:15 as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 09Apr2021 at 21:00, the patient experienced fever - 102.4 degrees Fahrenheit(F), moderate fatigue, severe headache, moderate chills, moderate muscle pain and moderate joint pain. The patient underwent lab test and procedures which included body temperature test on 09Apr2021 and the result was 102.4 F. No therapeutic measures were taken for the adverse events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events fever - 102.4 F, moderate fatigue, severe headache, moderate chills, moderate muscle pain and moderate joint pain was recovering at the time of this report.   No follow-up attempts are needed. No further information is expected.
An itchy rash developed between the patient's right elbow and right hand during the waiting period after vaccine administration.  The patient also said she thinks her eyes swelled up a little but did not sound too sure about that. I did not see such swelling.
Body aches and chills - 12/18 @ 10:00pm Fever 102.2. @ 3:00 Headache Dry heaves in morning 12/19 Slept all  day on 12/19 Temp 99.3 on 12/20 @ 8:00 am
Immediately got a metal taste in my mouth. The following day extremely sore arm and exhausted. All weekend felt ill. That Monday felt like I had extreme brain fog, to the point it was dangerous to drive. Muscle and joint pain. The weeks following and still continue is random shocks of pain all over my body and joint stiffness and pain.
This spontaneous report as received from a certified medical assistant refers to unspecified number of patients who were vaccinated with 3 doses of RECOMBIVAX HB (lot# not reported) as children. Patients were starting to attend college and had shown no immunity and are seronegative for anti-HBs antibodies. The patients sought medical attention via contacting office. Additional information is note expected.
Patient complained of nausea directly after administration of vaccine and vomited in office ; patient felt better after sitting for 5 minutes and headed home
Diffuse rash with small papules all over trunk, arms and legs with mild itching.  Employee presented to emergency room and was treated with benadryl and fomotadine for possible allergic reaction
Headache, Myalgia, Fever, Fatigue, Chills Narrative:
Pain at injection site starting approx. 1 hour after injection and continuing yesterday and today (3/29/21), fever, chills, and headache starting approx. 3-4 hours after injection and lasting approx. 12 hours, joint pain in right knee and right elbow starting approx. 24 hours after injection and continuing today (3/29/21).
Cognitive issues (fogginess, short term memory retention, noticeable reduction in motor control, difficulty maintaining conversation and threading thoughts, forming sentences, etc.); Persistent headache; This is a spontaneous report from a non-contactable consumer, the patient. A 32-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 02Jun2021 at 16:30 (at the age of 32-year-old) as a single dose for COVID-19 immunisation. Medical history included crohn's. Concomitant medication included adalimumab (HUMIRA) from an unknown date and for an unknown indication. The patient previously received cefixime (SUPRAX) on an unknown date and experienced allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 04Jun2021 at 09:00, the patient experienced cognitive issues (fogginess, short term memory retention, noticeable reduction in motor control, difficulty maintaining conversation and threading thoughts, forming sentences, etc.) and persistent headache. The patient did not have these cognitive problems normally. The patient's persistent headache did not respond to Tylenol. The patient did get periodic headaches but they did not last that long. Therapeutic measures were not taken as a result of cognitive issues. The clinical outcome of the events cognitive issues (fogginess, short term memory retention, noticeable reduction in motor control, difficulty maintaining conversation and threading thoughts, forming sentences, etc.) and persistent headache was not resolved at the time of this report.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Rash all over face and arms appeared 3 days later. It is now the 5th day and the rash has spread to my legs and stomach/very itchy and irritating; fatigue; This is a spontaneous report received from a contactable consumer (Reporting for herself). A 17-years-old female patient received Second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Formulation: Solution for injection, Lot number: EM9810, Expiration date: not reported) via an unspecified route of administration in Arm Left on 13Feb2021 12:45 (At the age of 17 years-old) as single dose for COVID-19 vaccination. The patient medical history was not reported and no known allergies. The historical vaccine included first dose of BNT162B2 received via an unspecified route of administration in Arm Left on 23Jan2021 12:30 for COVID-19 vaccination. The patient's concomitant medications were not reported. The patient was not pregnant at the time of vaccination. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. No COVID prior vaccination. No COVID tested post vaccination. It was reported that patient had no symptoms after the 1st dose.   On 16Feb2021 she had fatigue (the first 1-2 days after getting the 2nd dose of Pfizer) that got better. Rash all over face and arms appeared 3 days later. It is now the 5th day and the rash has spread to legs and stomach. It was beginning to get very itchy and irritating. Patient was treated with hydrocortisone 3-4 times a day and it was not of much help. The outcome of the events was not recovered.
No additional AE details were provided and no additional AE's were reported; patients that were administered vaccines after they were involved in a TE.; This spontaneous report was received from a licensed practical nurse and referred to a 9-week-old patient of unspecified age. The patient's medical history, concurrent conditions, concomitant therapies were not reported.  On 08-NOV-2022 at 13:00, the patient was vaccinated with rotavirus vaccine, live, oral, pentavalent (ROTATEQ), 2 milliliter oral liquid, 2 milliliter, lot #1879861, expiration date: 20-OCT-2023, administered orally for prophylaxis after the vaccine was involved in a temperature excursion (Product storage error). The storage temperature of the rotavirus vaccine, live, oral, pentavalent (ROTATEQ) was 11.4 degrees Celsius for a time frame of 1 hour 30 minutes. There was no previous temperature excursion. No additional adverse effect (AE) details were provided (no adverse event).  This is one of 9 reports received from the same reporter. ; Sender's Comments:  US-009507513-2212USA000031: US-009507513-2212USA000033: US-009507513-2212USA000034: US-009507513-2212USA000035: US-009507513-2212USA000036: US-009507513-2212USA000037: US-009507513-2212USA000038: US-009507513-2211USA004171:
I tested positive for COVID-19, August 23, 2022. I had really mild symptoms. I was sneezing a lot and a slight fever around 99.  I contacted my doctor the same day and he prescribe me Paxlovid the same day. I was instructed to take the Paxlovid for five days straight.
Patient is experiencing fatigue and soreness at injection site. Patient was given 0.2ml of undiluted Pfizer pediatric vaccine. Patient was instructed to treat symptoms, pain reliever and rest as appropriate.
Felt a surge then it was like someone was grabbing my throat; 15 minutes after receiving the second shot I felt a surge; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a patient and describes the occurrence of OROPHARYNGEAL DISCOMFORT (Felt a surge then it was like someone was grabbing my throat) and FEELING ABNORMAL (15 minutes after receiving the second shot I felt a surge) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced OROPHARYNGEAL DISCOMFORT (Felt a surge then it was like someone was grabbing my throat) and FEELING ABNORMAL (15 minutes after receiving the second shot I felt a surge). At the time of the report, OROPHARYNGEAL DISCOMFORT (Felt a surge then it was like someone was grabbing my throat) and FEELING ABNORMAL (15 minutes after receiving the second shot I felt a surge) outcome was unknown. Not Provided          Concomitant product use was not provided by the reporter.  Treatment information was not provided.   This case was linked to MOD-2021-270804 (Patient Link).
100+ fever for 24 hours gradually returning to normal temp, full body muscle aches that made laying down in any position very uncomfortable, very hindering headache, short of breath but lungs seemed to be fine mainly painful due to muscle aching and worsening the headache with deeper breaths.
Patient is a 59 y.o. male with a PMH significant for HTN, HLD, PE on anticoagulation who was admitted at hospital for Covid pneumonia and developed a L MCA stroke. Per report patient last seen well at 9:30 am, at around ~ 12:30 he had an aspiration event and became hypoxic. At that time he was also noted to have left sided weakness. CT head was reportedly negative. No tPA was given since he was on anticoagulation
Pt had a RXN (R) thigh with fever would not bear any weight on his (R) leg.
Chest pain that began the morning of 10/15, resolved with ibuprofen. admitted to the hospital for further evaluation
Shortness of breath; This spontaneous case was reported by a consumer and describes the occurrence of DYSPNOEA (Shortness of breath) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced DYSPNOEA (Shortness of breath). At the time of the report, DYSPNOEA (Shortness of breath) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No relevant concomitant medications were reported. Treatment information was unknown.
urine had a very strong odor like after eating a lot of asparagus; soreness in arm; felt a little tired; a little headache; This spontaneous case was reported by a consumer and describes the occurrence of URINE ODOUR ABNORMAL (urine had a very strong odor like after eating a lot of asparagus), MYALGIA (soreness in arm), FATIGUE (felt a little tired) and HEADACHE (a little headache) in a 63-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.  Concomitant products included ATORVASTATIN, FAMOTIDINE, HYDROCHLOROTHIAZIDE, LISINOPRIL (LISINOPRIL/HCTZ), VITAMIN D NOS, ALPHA LIPOIC ACID and FISH OIL for an unknown indication.    On 03-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced URINE ODOUR ABNORMAL (urine had a very strong odor like after eating a lot of asparagus), MYALGIA (soreness in arm), FATIGUE (felt a little tired) and HEADACHE (a little headache). At the time of the report, URINE ODOUR ABNORMAL (urine had a very strong odor like after eating a lot of asparagus), MYALGIA (soreness in arm), FATIGUE (felt a little tired) and HEADACHE (a little headache) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No treatment information was provided.
significant development of swelling and erythema, with pain and heat at the site of administration of the vaccine
Diagnosis of Covid-19 two weeks after administration of the vaccine; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a pharmacist (subsequently medically confirmed) and describes the occurrence of SARS-COV-2 TEST POSITIVE (Diagnosis of Covid-19 two weeks after administration of the vaccine) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 29-Dec-2020, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced SARS-COV-2 TEST POSITIVE (Diagnosis of Covid-19 two weeks after administration of the vaccine). At the time of the report, SARS-COV-2 TEST POSITIVE (Diagnosis of Covid-19 two weeks after administration of the vaccine) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Concomitant medications were not provided. Treatment medications were not provided.; Sender's Comments: Very limited information regarding this event has been provided at this time. The patient probably experienced asymptomatic COVID-19 infection before being administered with the mRNA-1273 vaccine
Patient experienced shingles approximately 3 weeks after getting the shot, followed by congestion in the throat, followed by itching on the back that is still occurring.
sore throat; dizziness; Horrible rash; vomits; Headache; This spontaneous case was reported by a consumer and describes the occurrence of OROPHARYNGEAL PAIN (sore throat), DIZZINESS (dizziness), RASH (Horrible rash), VOMITING (vomits) and HEADACHE (Headache) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 03-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced OROPHARYNGEAL PAIN (sore throat), DIZZINESS (dizziness), RASH (Horrible rash), VOMITING (vomits) and HEADACHE (Headache). At the time of the report, OROPHARYNGEAL PAIN (sore throat), DIZZINESS (dizziness), RASH (Horrible rash), VOMITING (vomits) and HEADACHE (Headache) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant product information, if any, was not provided by the reporter.  Treatment information, if any, was not provided.
16OCT had blotching on face, chin arms; denies fever; mild pruritis; seen by MD on 17OCT;
rash at injection site -red, raised, 3 inches long by 2 inches wide at injection site on left upper arm.
Dry mouth; Nausea; This spontaneous case was reported by a consumer and describes the occurrence of DRY MOUTH (Dry mouth) and NAUSEA (Nausea) in an adult female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) solution for injection for Rheumatoid arthritis.    No Medical History information was reported.   In 2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form and dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form and ADALIMUMAB (HUMIRA) (Subcutaneous) at an unspecified dose. On an unknown date, the patient experienced DRY MOUTH (Dry mouth) and NAUSEA (Nausea). At the time of the report, DRY MOUTH (Dry mouth) and NAUSEA (Nausea) outcome was unknown.            No concomitant medications were reported. The booster dose was administered on unknown date of 2022. It was reported that daily dose of HUMIRA was Citrate free. it was unknown if patient was enrolled in a COVID-19 Vaccine trial. No treatment medications were provided.
PATIENT RECEIVED VACCINE FROM OUTSIDE SOURCE ACUTE DVT OF RIGHT LEG, UNSPECIFIED VEIN HYPOTENSION
This spontaneous report as received from a medical assistant refers to a patient of unknown age and gender. The patient's medical history and concurrent conditions were not reported. On 17-JAN-2018, the patient was vaccinated with improperly stored ROTATEQ (lot # N010706, expiry date: 02-DEC-2018) (route: oral) (incorrect product storage). The vaccine was exposed to a temperature of 9 Cº to 25 Cº (8.3Cº) for 1 hour 17 min, on 06-JAN-2018, 9 Cº to 25 Cº (11.5Cº) for 1 hour 59 min on 11-JAN-2018, 9 Cº to 25 Cº (15.6Cº) for 1 hour 33 min on 17-JAN-2018, 9 Cº to 25 Cº (11.9Cº) for 1 hour 2 min on 23-JAN-2018 and 9 Cº to 25 Cº (12.1Cº) for 1 hour on 30-JAN-2018. There was no previous temperature excursion. The call was because of a data logger. No adverse effects reported. The outcome of the event was unknown. This is one of the several reports received from the same reporter. Sender's Comments: US-009507513-1802USA004616: US-009507513-1802USA004629: US-009507513-1802USA004634: US-009507513-1802USA004636: US-009507513-1802USA004641: US-009507513-1802USA004647: US-009507513-1802USA004652: 1802USA004654: Original Case: 1802USA002182 US-009507513-1802USA004654: US-009507513-1802USA004658: US-009507513-1802USA004663: US-009507513-1802USA004671: US-009507513-1802USA004673: US-009507513-1802USA004686: US-009507513-1802USA004692.
Numbness in the entire left side of body; Not walking steady; This spontaneous case was reported by a consumer and describes the occurrence of HYPOAESTHESIA (Numbness in the entire left side of body) and GAIT DISTURBANCE (Not walking steady) in an 89-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 016M20A) for COVID-19 vaccination.     No Medical History information was reported.    On 14-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 14-Feb-2021, the patient experienced HYPOAESTHESIA (Numbness in the entire left side of body) and GAIT DISTURBANCE (Not walking steady). At the time of the report, HYPOAESTHESIA (Numbness in the entire left side of body) and GAIT DISTURBANCE (Not walking steady) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant medication included unspecified blood pressure medications.  No treatment information was provided.
discomfort from swollen lymph nodes; This spontaneous case was reported by a consumer and describes the occurrence of LYMPHADENOPATHY (discomfort from swollen lymph nodes) in a 50-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 04-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 08-Mar-2021, the patient experienced LYMPHADENOPATHY (discomfort from swollen lymph nodes). At the time of the report, LYMPHADENOPATHY (discomfort from swollen lymph nodes) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No relevant concomitant medications were reported.  Treatment information was not provided.
swell of upper arm & underneath side of arm;taking Ibuprofen-ice 5MAR & 6MAR; DPH-oral per MD
Injection site shows a subdeltoid mass effect of 5-6 cm with moderate tenderness. Pt c/o increased pain with ROM of shoulder. Pt also c/o severe sore throat. Temp of 100.6.